生物活性 | |||
---|---|---|---|
描述 | Fmoc-leucine serves as a selective modulator of PPARγ, triggering its activation with less potency yet comparable maximal effectiveness to that of rosiglitazone. It enhances insulin sensitivity across various mouse models, including normal, diet-induced glucose-intolerant, and diabetic db/db mice. Additionally, Fmoc-leucine is characterized by reduced adipogenic activity[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.83mL 0.57mL 0.28mL |
14.15mL 2.83mL 1.41mL |
28.30mL 5.66mL 2.83mL |
参考文献 |
---|